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Abstract
While targeted therapy brought a new era in the treatment of BRAFmutant melanoma, therapeu-
tic options for non-BRAFmutant cases are still limited. In order to explore the antitumor activity of
prenylation inhibition we investigated the response to zoledronic acid treatment in thirteen human
melanoma cell lines with knownBRAF, NRAS and PTENmutational status. Effect of zoledronic
acid on proliferation, clonogenic potential, apoptosis andmigration of melanoma cells as well as
the activation of downstream elements of the RAS/RAF pathwaywere investigated in vitrowith
SRB, TUNEL and PARP cleavage assays and videomicroscopy and immunoblot measure-
ments, respectively. Subcutaneous and spleen-to-liver colonization xenograft mousemodels
were used to evaluate the influence of zoledronic acid treatment on primary and disseminated
tumor growth of melanoma cells in vivo. Zoledronic acid more efficiently decreased short-term in
vitro viability in NRASmutant cells when compared to BRAFmutant and BRAF/NRASwild-type
cells. In line with this finding, following treatment decreased activation of ribosomal protein S6
was found in NRASmutant cells. Zoledronic acid demonstrated no significant synergism in cell vi-
ability inhibition or apoptosis induction with cisplatin or DTIC treatment in vitro. Importantly, zole-
dronic acid could inhibit clonogenic growth in themajority of melanoma cell lines except in the
three BRAFmutant but PTENwild-typemelanoma lines. A similar pattern was observed in apo-
ptosis induction experiments. In vivo zoledronic acid did not inhibit the subcutaneous growth or
spleen-to-liver colonization of melanoma cells. Altogether our data demonstrates that prenylation
inhibitionmay be a novel therapeutic approach in NRASmutant melanoma. Nevertheless, we
also demonstrated that therapeutic sensitivity might be influenced by the PTEN status of BRAF
mutant melanoma cells. However, further investigations are needed to identify drugs that have
appropriate pharmacological properties to efficiently target prenylation inmelanoma cells.
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Introduction
Melanoma is characterized by high mortality among solid tumors due to the very high meta-
static potential of melanoma cells and their resistance to therapy especially at late stage diseases
[1, 2]. The three-year survival among patients with visceral metastases is less than 20% [3, 4].
Importantly, the majority of melanoma cases demonstrate oncogenic activation of the
KIT—NRAS—BRAF—MEK—ERK central axis [5] that is a major regulator of cell differentia-
tion and proliferation [6, 7]. The importance of this pathway is highlighted by the finding that
BRAF and NRAS mutation are the two most important oncogenic mutations in melanoma and
both of these mutations result in the constitutive activation of the RAS-RAF-MEK-ERK signal-
ing cascade. BRAF mutation is detected in about 40 to 70% of the cases while NRAS mutation
is present in 10 to 30% of melanomas [8–15]. In addition, RAS activates also the protein kinase
B/Akt pathway where PTEN, a tumor-suppressor, acts as an endogenous inhibitor by catalyz-
ing the PIP3 to PIP2 transformation thus counteracting PI3K [16]. PTEN-null mutations are
present in 20% of melanoma cases [17, 18] furthermore PTEN null mutation is often concur-
rent with BRAF mutation in melanoma [19].
Accordingly, inhibitors of the RAS-RAF-MEK-ERK pathway carry great promises for anti-
cancer treatment. However, due to the mechanism of Ras activation and signal transmission
the direct targeting of the Ras protein is rather difficult [20]. Ras protein needs to be processed
in the endoplasmic reticulum and transported to the cell membrane to exert its function.
Thus, the posttranslational modification and the anchorage to the cell membrane of Ras are
among the most intensely targeted steps in Ras-related tumor treatments [21].
For instance, S-farnesylthiosalicylic acid (FTS, Salirasib) competes with Ras for Ras-anchorage
sites at the cell membrane and reduces Ras-dependent tumor growth [22]. However, the mecha-
nism and the selectivity against activated Ras is still under investigation [23, 24]. One approach is
the inhibition of farnesyltransferases that results in the inhibition of the thioether linked addition
of an isoprenyl group to the CAAX-box cystein of Ras. These inhibitors showed great promise in
preclinical models but failed to succeed in monotherapy clinical trials [25, 26]. One reason for the
failure of this approach is that in human cancer cells treated with farnesiltransferase-inhibitors
(FTIs), K-Ras and possibly N-Ras (but not H-Ras) become geranylgeranylated [27–29]. As a con-
sequence, the blockade of Ras activation requires the inhibition of both farnesyltransferase and
geranylgeranylase [30].
Bisphosphonates, a class of synthetic analogues of the endogenous pyrophosphate, inhibit
the posttranslational modification of Ras proteins by blocking the intracellular key enzyme of
the mevalonate pathway, farnesyl diphosphate syntase. This enzyme is responsible for the pro-
duction of cholesterol and isoprenoid lipids such as farnesyl diphosphate and geranylgeranyl
diphosphate [31, 32]. These isoprenoids are necessary for the post-translational lipid modifica-
tion (prenylation) of Ras proteins including both farnesylation and geranylgeranylation. One
of the clinically applied amino-bisphosphonates is zoledronic acid that is currently established
in the treatment for bone lesions and metastases of a number of cancers.
An increasing number of both in vitro and in vivo studies suggest that bisphosphonates, espe-
cially nitrogen containing bisphosphonates such as pamidronate or zoledronate, may also have
a specific antitumoral activity. Bisphosphonates have shown potential to inhibit proliferation, in-
duce cell cycle changes and/or induce apoptosis in several studies on myeloma cells both in vitro
[33–37] and in vivo [38]. Similar effects of bisphosphonate treatment were reported for osteosar-
coma, prostate or breast carcinoma cells [34, 39–43]. In preclinical studies cancer types without
preferential spreading to bone were also treated effectively with bisphosphonates. Pancreatic can-
cer cells [44] and even neural crest derived neuroblastoma cells [45] have shown sensitivity to
zoledronic acid treatment. Very recently, zoledronic acid was proven to enhance the effect of
Prenylation Inhibition-Induced Cell Death in Melanoma
PLOSONE | DOI:10.1371/journal.pone.0117021 February 3, 2015 2 / 18
János Bolyai Research Scholarship of the Hungarian
Academy of Sciences. The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
EGFR-inhibitors and even to overcome resistance acquired through the gatekeeper mutation
T790M in non-small cell lung cancer, breast cancer and colorectal cancer [46, 47].
In melanoma the aminobisphosphonate pamidronate was able to inhibit proliferation and
induce apoptosis [48]. Furthermore the treatment of melanoma cells with nitrogen-containing
bisphosphonates (pamidronate and zoledronate), but not the treatment with nonaminobispho-
sphonates (clodronate) resulted in decreased cell proliferation in vitro [49]. Nevertheless, the
effect of zoledronic acid on melanoma cells in vivo and the dependence of biological response
on the BRAF or NRAS oncogenic mutation status have not yet been studied.
Accordingly, we determined the impact of BRAF, PTEN and NRAS mutation on the effect
of zoledronic acid treatment on cell viability, clonogenic growth, apoptosis induction, cell mi-
gration and activation of the downstream signaling pathway in melanoma cells in vitro and on
primary tumor growth and spleen-to-liver colonization in mice models of human melanoma
cells in vivo.
Methods
Cell lines and culture conditions
Thirteen human melanoma cell lines were used in the experiments. HT168-M1 melanoma line
was a highly metastatic derivative from the A2058 cell line isolated in liver colonization model
of mice [50]. The BRAF mutant/PTEN-null HT199 melanoma cell line was developed at the
Semmelweis University, Budapest Hungary [51]. The M24met melanoma line (NRAS mutant),
established from an invaded lymph node of a nude mouse [52], was kindly provided by
B. M. Mueller (Scripps Research Institute, La Jolla, CA). VM-15 (NRAS mutant) and VM-47
(wild-type) cell lines were established at Institute of Cancer Research, Vienna, Austria from
lymph node and brain metastasis, respectively [53, 54]. The melanoma cell lines A375, A2058,
LOX (BRAF mutant) and MEWO (wild-type) are available from ATCC. WM3060, WM3670
(NRAS/BRAF mutant), WM35 andWM239 cell lines were obtained from the Wistar Institute.
The mutational status of cell lines is presented in Table 1. Cell cultures were maintained in
DMEM (Lonza, Switzerland; with 4500mg/dm3 glucose, piruvate and L-glutamine) supple-
mented with 10% fetal calf serum (Lonza) and 1% penicillin-streptomycin-amphotericyn
(Lonza) in tissue culture flasks at 37C in a humidified 5% CO2 atmosphere.
Table 1. Mutational status of all 13 human melanoma cell lines.
BRAF NRAS PTEN REFERENCE
MEWO wt wt + [74](NF1 mutant)
VM47 wt wt + (weak) own sequence
WM3060 wt 61K + [75]
VM15 wt 61K + (weak) own sequence
M24met wt 61R + own sequence
WM3670 G469E 12D + [75]
WM35 V600E wt + [65, 76]
LOX V600E wt + [77]
A375 V600E wt + [77]
HT168-M1 V600E wt - own sequence
A2058 V600E wt - [77]
WM239 V600E wt - [65, 76]
HT199 V600E wt - own sequence
doi:10.1371/journal.pone.0117021.t001
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Mutational analysis
PCR reaction to multiply BRAF and NRAS genes were performed with from the cell lines iso-
lated DNA in cell lines with no previously published mutational status. In a consecutive step
samples were purified with Applied Biosystems BigDye XTerminator Purification Kit and mu-
tations were verified through sequencing on Abi 3130 Genetic Analyzer System with BigDye
Terminator v1.1 Kit. Loss of PTEN was shown using immunoblot analysis (S1 Fig.).
Proliferation (SRB) assay
To analyze short time effect of zoledronic acid (ZA) on cell proliferation Sulforhodamine
B (SRB) assay was performed based on the measurement of cellular protein content. Briefly,
melanoma cells were plated in the inner 60 wells of a 96-well plate. After 24hs in control medium
and 72hs treatment with zoledronic acid, cell monolayers were fixed with 10% trichloroacetic
acid and stained for 15 min with SRB. Cells were repeatedly washed with 1% (vol/vol) acetic acid
to remove excess dye. The protein-bound dye was dissolved in 10 mMTris and OD determined
at 570 nm using a microplate reader (EL800, BioTec Instruments, Winooski, VT). Data shown
as average of six independent experiments and effect of treatment is expressed relative to control.
Clonogenic assay
Long time antiproliferative effect of ZA treatment was assessed by performing clonogenic
assay. Briefly, 1000 cells (for LOX, WM3060, WM3670, VM-47 cells 10000 cells) were seeded
in 6 well plates and treated 5μMZA for 10 days. Fresh medium and ZA were supplied on each
3rd day. On the 10th day cells were fixed with 10% trichloroacetic acid and stained and mea-
sured as in the SRB assay.
Apoptosis detection by TUNEL-staining
For apoptosis detection cells were set on 24 well plates and treated with either zoledronic acid
and/or a cytotoxic agent (DTIC or cisplatin). After 48hs of treatment cells were fixed with
4% buffered PFA and labeling of terminal deoxynucleotidyl transferase—mediated dUTP nick
end labeling (TUNEL) was performed according to the manufacturer’s instructions (Roche
Diagnostics, Basel, Switzerland). Quantification was done by direct counting of the TUNEL-
positive cells on at least five 20× microscopic fields.
Time-lapse videomicroscopy
Videomicroscopy measurements were performed and analyzed as described previously
[55–57]. Briefly, melanoma cells were plated in the inner 8 wells of 24-well plates (Corning In-
corporated, Corning, NY) in DMEMmedium supplemented with 10% FCS. The medium was
changed to CO2-independent medium (Gibco-BRL Life Technologies, Carlsbad, CA) with
10% FCS and 4mM glutamine after the overnight cell attachment. In order to reduce evapora-
tion from the inner wells, the outer wells were filled with medium. Cells were kept in a custom
designed incubator built around an inverted phase-contrast microscope (World Precision In-
struments, Sarasota, FL) at 37°C and room ambient atmosphere. Images of 3 neighboring mi-
croscopic fields were taken in every 5 min for 1 day before and 2 days after the treatment with
zoledronic acid, dacarbazine or both. For migration data the captured phase contrast micro-
scope pictures were analyzed individually with a cell-tracking program enabling manual mark-
ing of individual cells and recording their position parameters into data files. The parameter
migrated distance is calculated by averaging for each cell the displacement for the first 24 hour
interval after treatment, in two independent experiments and 3 microscopic fields.
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Immunoblot analysis
Immunoblot analysis was performed to examine the expression of PTEN, the induction of apo-
ptosis by PARP cleavage and the phosphorylation of Erk1/2 and S6 proteins, two downstream
targets of the RAS pathway. Cells were set in six-well plates and maintained as mentioned
above. After two days of incubation time cells were treated in two independent replicates for
12h with zoledronic acid, dacarbazin or both for the measurement of the activation of down-
stream effectors ERK1/2 and S6. 48hs ZA treatment was applied for the assessment of apopto-
sis and untreated cells were used for the evaluation of PTEN expression on the protein level.
Cells were lysed with RIPA Buffer (Thermo Scientific, Waltham, MA) supplemented with
1% Halt Protease Inhibitor Single-Use Cocktail (Thermo Scientific). Total protein concentra-
tions were determined with Pierce BCA Protein Assay kit (Thermo Scientific), denatured and
equal amounts of protein were size-fractionated by SDS-PAGE (12%) and transferred to nitro-
cellulose membrane (Whatman, Maidstone, UK) The membranes were incubated with anti
PTEN (Cell Signaling; # 9552), anti cleaved-PARP (Cell Signaling; # 9541) and anti p-Erk/Erk,
p-S6/S6, p-Akt and as loading control anti β-tubulin (Cell Signaling; #9101, #9102, #2215,
#2217, #4058 and # 2128 respectively), overnight at 4°C in a dilution of 1:2000. Secondary,
HRP labeled anti-rabbit antibody was applied 1:2000 for 0,5h at room temperature. Visualiza-
tion was achieved with Amersham ECL Advance Western Blotting Detection kit (GE
HealthCare, Little Chalfont, UK). Activation of signaling was quantified as the ratio of phos-
phorylated and total protein densitometry measurements using ImageJ software.
Subcutaneous xenografts of human melanoma cells
All animal-model protocols were carried out in accordance with the Guidelines for Animal Ex-
periments and were approved for the Department of Experimental Pharmacology in the Na-
tional Institute of Oncology, Budapest, Hungary (permission number: 22.1/722/3/2010).
HT168-M1, M24met and MEWO human melanoma cells (106 HT168-M1 andMEWO,
105 M24met) were subcutaneously injected in male SCIDmice, at a weight of 30–33g and 10 ani-
mals per group. Since the HT168-M1 xenografts tend to outgrew rapidly mice transplanted with
HT168-M1 were treated and sacrificed earlier. After randomization, animals were treated intra-
peritoneally weekly for three weeks. The treatment with zoledronic acid started when first tu-
mors were measurable, consequently at day 10 for mice injected in with HT168-M1 or after two
weeks for animal treated with M24met or MEWO. Controls received 100 μl of 0.9% NaCl. The
subcutaneous tumors were measured with a caliper and tumor-volumes were calculated with the
formula for the volume of a prolate ellipsoid (length ×width2 π/6) and expressed in cm3. After
the last measurement of subcutaneous tumors animals were sacrificed by cervical dislocation.
Spleen to liver colonization assay
Melanoma cells (5×102 HT168-M1, 105 M24met or 106 MEWO) were injected into the spleen
of male SCID mice under Nembutal anesthesia, 10 animals per group. Zoledronic acid
(500 μg/kg) or saline as control was administered intraperitoneally from the 7th day for
HT168-M1 and from the 10th day for M24met and MEWO cells post injection day and contin-
ued for 3 weeks. After 3 weeks of treatment animals were sacrificed by cervical dislocation,
spleen and liver were removed and total weight of organs assessed.
Statistics
To determine statistical differences between groups, ANOVA was performed for datasets with
normal distribution and Dunnett’s post hoc test and Tukey’s post hoc test were computed if
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comparison to control or to each treated group, respectively, was questioned. Otherwise, non-
parametric Kruskal-Wallis and post hoc Dunn’s multiple comparison test was used. Unpaired
T test was calculated for the statistical evaluation of the treatment, if only one treatment was
analyzed. Statistical significance was established at p< 0.05. All statistical analyses were com-
puted in GraphPad Prism 5 (GraphPad Software Inc, USA, San Diego, CA).
Results
Mutational status dependent inhibition of in vitro growth by zoledronic
acid (ZA)
Altogether thirteen human melanoma cell lines with different NRAS, BRAF and PTEN muta-
tional status (Table 1 and S1 Fig.) were treated with the prenylation inhibitor zoledronic acid
(ZA). Short-term effect of the treatment with different concentrations of ZA on cell prolifera-
tion of melanoma cells was measured by SRB-assay (Fig. 1A). ZA treatment clearly decreased
cell viability in two NRAS mutant melanoma lines at relatively smaller doses. At the same time
the lowest sensitivity was demonstrated by two BRAF mutant and PTEN wild-type lines.
However, there was no equivocal correlation between oncogenic mutations and sensitivity to
short-term ZA treatment on cell viability. Long-term effect of ZA treatment was measured by
clonogenic assay (Fig. 1B). As expected NRAS mutant cells showed high sensitivity to ZA.
Of note, sensitivity of BRAF mutant cells to ZA treatment depended on their PTEN mutational
status. All four BRAF mutant/PTEN-null mutant cells were sensitive to long-term ZA
treatment in contrast to three BRAF mutant and PTEN wild-type line that were essentially re-
sistant against prenylation inhibition. The NRAS and BRAF mutant but PTEN wild-type
WM3670 cells showed intermediate sensitivity. Importantly, when the reduction in clonogenic
potential was averaged for the mutational subtypes, NRAS, BRAF mutant/PTEN-null and tri-
ple wild-type cells were significantly higher as compared to BRAF mutant PTEN wild-type
cells (p< 0.0001 by Kruskal-Wallis and Dunn’s post hoc test).
In order to characterize the pro-apoptotic effect of ZA, TUNEL staining was performed
after 72 hours treatment with 25μMZA and the percentage of TUNEL positive cells evaluated
(Fig. 1C). In general, there was a more profound pro-apoptotic effect of ZA treatment in NRAS
and BRAF mutant/PTEN-null cells as compared to BRAF mutant PTEN wild-type cells. Of
note, despite its limited clonogenic growth, the MDM2 overexpressing WM239 line failed to
show robust apoptotic response. Increase in TUNEL positivity was seen also in both of the tri-
ple wild-type cell lines. The amount of apoptotic cells found in the TUNEL assay was in line
with the reduction in cell viability measured in the clonogenic assay. Level of apoptosis induc-
tion after ZA treatment was also evaluated by the immunoblot staining of cleaved PARP, a tar-
get of the apoptosis effector caspase-3 (Fig. 1D). Similarly to the results of TUNEL assay,
induced apoptosis correlated with the results of the long-term clonogenic growth measure-
ments. The smallest degree of apoptosis induction could be shown in BRAF mutant and PTEN
wild-type cells, and again, in WM239 cells.
Migration is not inhibited by zoledronic acid in melanoma cells
Videomicroscopy measurements were used to evaluate the effect of ZA treatment on migration
in one BRAF mutant and PTEN wild-type, two BRAF mutant and PTEN-null, two NRAS
mutant and two triple wild-type melanoma cell lines. Average migrated distance of the
cells—grouped by mutational status—was depicted as a function of time interval from 15 min-
utes to 20 hours (Fig. 2 A–C). Furthermore, relative average migrated distance for 24 hours
was calculated for each cell line (Fig. 2 D). ZA treatment increased the migratory activity of
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Fig 1. Cell viability, clonogenic growth and apoptosis in melanoma cells after zoledronic acid treatment. (A) Dose-response analysis of cell viability of
humanmelanoma cell lines with different mutations after 72hs treatment with ZAmeasured by SRB assay; Most pronounced reduction in cell viability was
observed in two NRASmutant lines (B) Long-term effect of 10 days of 5 μM ZA treatment on clonogenic growth. Resistance was found in BRAFmutant and
PTEN wild-type cells. Of note, NRAS and BRAF double mutant cells demonstrated intermediate sensitivity (C) Apoptosis induction after 25μM ZA treatment
demonstrated by the proportion of TUNEL positive cells and (D) apoptosis induction of 72hs ZA treatment evaluated by the immunoblot of cleaved PARP.
Limited apoptosis induction was found in BRAFmutant and PTENwild-type cells and in the MDM2 over expressingWM239 cells. Colors green, red, blue,
and dark-blue indicate triple wild-type, NRAS, BRAF, and BRAFmutant/PTEN-null mutational status of the cells, respectively. Data shown as average ±
SEM are from at least 5 repeats. Asterisks indicate the lowest concentration of ZA treatment resulting in a significant difference with p< 0.05 from control by
ANOVA and Dunnett’s post hoc test in the cell viability assay. Data shown as average ± SEM are from at least 3 measurements. Asterisks indicate significant
difference of p< 0.05 between given mutational group and the BRAFmutant PTEN wild-type group by Kruskal-Wallis and Dunn’s post hoc test in the
clonogenic assay, and p< 0.05 difference from the respective control by unpaired two tailed T test in the apoptosis assay. (C = control; Z = zoledronic acid).
doi:10.1371/journal.pone.0117021.g001
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BRAF-mutant cells to a much higher extent compared to NRAS mutant and double wild-type
cells. Significant increase in average migrated distance was measured in VM-47, VM-15, A375,
A2058 and HT168-M1 cells by unpaired t-test (p = 0.0086, p = 0.0116, p = 0.0091, p = 0.0495,
and p = 0.0065, respectively). When migration was compared by mutational status, the increase
in average migrated distance was significant (p = 0.0427 by unpaired t-test) in BRAF
mutant cells.
Effect of ZA on Erk and S6 activation in melanoma cells
To investigate the effect of ZA on the major signaling cascades that are regulated by oncogenic
BRAF or NRAS we performed immunoblot analysis of the activation of two major downstream
effectors of the RAS-RAF-MEK and the PI3K-AKT-mTOR pathway, the Erk1/2 and the ribo-
somal protein S6 proteins, respectively (Fig. 3). Surprisingly, 48 hours of ZA treatment in-
creased activation of Erk1/2 in MEWO and M24met cells and to a smaller extent in BRAF
Fig 2. Cell migration after zoledronic acid treatment in melanoma cells. (A-C) Migrated distance as a function of time and (D) average migrated distance
after zoledronic acid (ZA) treatment in melanoma cells measured by videomicroscopy. A profound and significant increase in migrated distance was found in
all of the BRAFmutant cells. A modest but significant increase in migration was found in VM-47 triple wild-type and VM-15 NRASmutant cells. Colors blue,
red and green indicate BRAF, NRASmutation and wild-type for these genes, respectively. Data shown as average ± SEM are from at least three
independent measurements. Asterisks indicate significant difference of p< 0.05 from the respective control with unpaired two-tailed T test.
doi:10.1371/journal.pone.0117021.g002
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mutant cells. The treatment with ZA resulted in decreased activation of S6 in NRAS mutant
cells. The more sensitive M24met cells showed higher decrease than the less sensitive NRAS
mutant VM-15 cells. Furthermore, both NRAS mutant cell line had lower level of Akt phos-
phorylation after ZA treatment (S2 Fig.).
Effect of combination of zoledronic acid (ZA) and cytotoxic compounds
in vitro
To investigate the potential synergistic effect of prenylation inhibition with cytotoxic therapy,
ZA treatment was applied concurrently with DTIC or cisplatin on three human melanoma cell
lines with BRAF or NRAS mutation or harboring no mutations of these genes.
Fig 3. Activation of downstream elements of the RAS/RAF pathway in melanoma cells after zoledronic acid treatment. (A) Representative blots of
the effect of 48hs zoledronic acid (ZA) treatment on the activation of Erk1/2 and S6. (B) Quantification of the effect of ZA treatment on the activation of Erk1/2.
Treatment with ZA resulted in robust increase in the phosphorylation of Erk1/2 in MEWO and M24met cells. (C) Quantification of the effect of ZA treatment on
the activation of S6. After the treatment with ZA, decreased activation of S6 proteins was found only in NRASmutant M24met and VM-15 cells. Colors blue,
red and green indicate BRAF, NRASmutation and wild-type for these genes, respectively. (C = control; ZA = zoledronic acid).
doi:10.1371/journal.pone.0117021.g003
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DTIC and cisplatin significantly reduced proliferation in all examined cell lines (p< 0.05 by
Kruskal-Wallis and Dunn’s post hoc test) based on the SRB assay (Fig. 4A). There was a signifi-
cantly increased reduction in proliferation measured after combination treatment as compared
to the single treatment in the NRAS mutant M24met line. In order to further evaluate the poten-
tial interaction we performed further combination experiments with an additional NRAS mutant
line (VM15). We could only demonstrate additive effects with either of the compounds (S3 Fig.).
In order to characterize the proapoptotic effect of these drugs, we performed TUNEL assay
(Fig. 4B). High proapoptotic effect of single agent ZA treatment in NRAS mutant cells was
found, and no additive effect with either cytotoxic compound was seen. DTIC had no effect on
ZA induced increase in cell migration in BRAFmutant cells (S4 Fig.). In NRAS mutant and dou-
ble wild-type cells neither the single nor the combined treatment changed migratory activity.
To investigate the effect of ZA in combination with cytotoxic drugs (DTIC or cisplatin) on
the major signaling cascades downstream of BRAF or NRAS immunoblot analysis of the activa-
tion the proteins Erk1/2 and the ribosomal protein S6 was performed (Fig. 5). 12 hours treatment
with cytotoxic agents decreased the activation of Erk1/2 in MEWO and M24met cells, double
wild-type and NRASmutant, respectively. In contrast DTIC or cisplatin and combined treat-
ment resulted in the increase of Erk1/2 and S6 activation in the BRAF mutant HT168-M1 cells.
S6 activation was increased in M24met and upon treatment with cisplatin also in MEWO cells.
Importantly synergism between ZA and cytotoxic treatment was seen only in M24met cells if
treated with DTIC and ZA andMEWO cells after the treatment with cisplatin and ZA.
Effect of zoledronic acid (ZA) treatment in vivo
To assess the effect of zoledronic acid on primary tumor growth we injected subcutaneously
human melanoma cells into the flank of SCID mice (Fig. 6A, C and E). ZA treatment failed to
reduce the growth of melanoma cells. Of note, BRAF mutant/PTEN-null HT168-M1 cells
showed a very rapid growth rate after the initial lag phase that prompted the early termination
of the experiment. To investigate the metastasis related effects of ZA, we used the spleen-to-
liver colonization model in SCID mice (Fig. 6B, D and F). ZA could not inhibit either the pri-
mary or the metastatic growth of melanoma cells.
Discussion
In earlier investigations, despite great promises, farnesyltransferase inhibitors (FTIs) showed lim-
ited efficacy in monotherapy clinical trials [2, 25, 26]. A number of studies have investigated why
targeting the major posttranslational molecular mechanism is not effective [58–60]. One impor-
tant mechanism of FTI-resistance is the alternative geranylgeranylation of K-Ras and possibly
N-Ras (but not H-Ras) [27–29]. Due to this alternative mechanism in order to efficiently prevent
RAS activation the dual inhibition of farnesyltransferase and geranylgeranylase is necessary [30].
According to our current knowledge, the prenylation of mutant N-Ras is also required to exert
its oncogenic function [21]. Zoledronic acid (ZA), a nitrogen containing bisphosphonate inhibits
the intracellular key enzyme of the mevalonate pathway, namely the farnesyl diphosphate syn-
tase and thus interfering with both farnesylation and geranylgeranylation. Accordingly we inves-
tigated the response of melanoma cells to ZA. First we examined ZA’s short-term (72 h) effect
on melanoma cells with various NRAS, BRAF and PTENmutation status, but the role of these
mutations on treatment response was not equivocal. Especially at lower concentrations a consid-
erable proportion of cells remained vital. However, long-term (10 days) treatment with low con-
centration (5 μM) ZA had strong antiproliferative effect on triple wild-type, NRAS mutant and
BRAFmutant/PTEN-null cell lines. We found also apoptosis induction in triple wild-type,
NRAS mutant and BRAFmutant/PTEN-null cell lines with the exception ofWM239 cells.
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Fig 4. Proliferation and apoptosis in melanoma cells after combination treatments. (A) Both cytotoxic compounds reduced proliferation significantly
after 48hs of treatment in three cell lines irrespective of oncogenic mutation using SRB assay. An additive effect of ZA and cytotoxic treatment was measured
in the NRASmutant M24met cells. (B) Proportion of TUNEL positive cells after combined treatment with ZA and standard cytotoxic therapy (DTIC or
cisplatin). No synergism was observed in any of the cell lines investigated. Data shown as average ± SEM are results of four independent measurements.
Asterisks indicate significance of p< 0.05 with Kruskal-Wallis and Dunn’s multiple comparison tests.
doi:10.1371/journal.pone.0117021.g004
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WM239 cells harbor no p53 mutation, but express extremely high amount of mdm2, that is re-
sponsible for the degradation of p53 and can therefore lead to an extremely low amount of apo-
ptosis despite the decrease in cell viability [61]. In case of BRAFmutant PTEN wild-type cells,
such as A375, we found only limited decrease in proliferation in vitro below the 25μM concentra-
tion similar to the study by Forsea et al.[49]. Interestingly, BRAFmutant/PTEN-null melanoma
cells showed much higher sensitivity to ZA treatment as PTEN wild-type BRAFmutant cells. In
line with our observation, the effect of PTEN loss on therapeutic sensitivity of melanoma cells
has been demonstrated earlier in case of other drugs. Interestingly, PTEN loss conferred resis-
tance against EGFR inhibitors in colorectal and lung cancer [62, 63], against herceptin in breast
cancer [64] or even BRAF inhibitors in melanoma [65].
Fig 5. Activation of downstream elements of the RAS/RAF pathway in melanoma cells after combination treatments. (A) Representative blots of the
effect of 12hs zoledronic acid (ZA) and/or DTIC/cisplatin treatment on the activation of Erk1/2 and S6. (B) Quantification of the effect of ZA and/or DTIC/
cisplatin treatment on the activation of Erk1/2. Treatment with cytotoxic agents decreased the activation of Erk1/2 in double wild type MEWO and NRAS
mutant M24met cells. DTIC or cisplatin and combined treatment resulted in the increase of Erk1/2 activation in BRAFmutant HT168-M1 cells.
(C) Quantification of the effect of ZA and or DTIC/cisplatin treatment on the activation of S6. DTIC or cisplatin treatment increased S6 activation in HT168-M1
cells. S6 activation was also increased in M24met and in the combination treatment with cisplatin also in MEWO cells. Synergism between ZA and cytotoxic
treatment was seen only in M24met cells if treated with DTIC and ZA and MEWO cells after the treatment with cisplatin and ZA.
doi:10.1371/journal.pone.0117021.g005
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Fig 6. In vivo effects of zoledronic acid treatment. Effect of zoledronic acid (ZA) treatment using in vivo
subcutaneous xenograft model of humanmelanoma cells in SCID mice (A, C, E). ZA treatment failed to show
effects in the subcutaneous growth of melanoma cells with either mutation. (B, D, F) Effect of ZA treatment
using in vivo spleen liver colonization model of humanmelanoma cells in SCID mice. ZA did not inhibit the
primary tumor or metastatic growth of melanoma cells. Data shown as average ± SEM.
doi:10.1371/journal.pone.0117021.g006
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In contrast to the in vitro proliferation inhibiting effect of ZA, we found no inhibition of primary
tumor growth in the subcutaneous xenograft models of investigated humanmelanoma cells in
vivo. The lack of antitumor effect of ZA in vivo on the NRASmutant and BRAFmutant and PTEN
null melanoma cells may be explained by the fact, that around 50–60% of ZA accumulates in the
skeleton and the remaining part is excreted in the first 24hs after drug administration [66, 67].
In vitro treatment with ZA resulted in increased migration activity of certain melanoma
cells that may confer increased invasiveness or metastatic potential. Thus, we addressed this
question in the in vivo spleen-to-liver colonization model that reflects certain aspect of metas-
tasis formation. However, we found no change in the liver colonization capacity after zoledro-
nic acid treatment.
In order to assess the role of the major oncogenic signaling pathways we measured the acti-
vation of the ribosomal protein S6 and the proteins Erk1/2 by immunoblot analysis In the two
NRAS mutant cell line with robust short-term response to ZA, decreased S6 activation was
found. However, we found no correlation between S6 activation levels and apoptosis induction
or long-term clonogenic potential changes. Interestingly, the activation of Erk1/2 showed an
inverse correlation with cell motility similarly to former observations on primary endothelial
cells where the deletion of Erk1/2 resulted in an inhibition of proliferation and migration [68].
A potential mechanism by which Erk1/2 activation can induce cell migration has been de-
scribed by Carragher and colleagues [69]. They demonstrated that FAK recruits activated Erk
to focal adhesion to activate calpain2. Subsequently, this protease contributes to the disassem-
bly of focal adhesion complexes and thus stimulating cell migration.
Furthermore in our study we have explored the feasibility of combining standard cytotoxic
treatments (DTIC or cisplatin) with ZA. Importantly, we found that the efficacy of combina-
tion treatment was also mutation dependent. An additive effect in inhibition of cell viability
was only found in NRAS mutant but not in BRAF mutant or double wild-type cells. Interest-
ingly, this additive effect of combination treatment was not seen in the apoptosis of NRAS mu-
tant cells. In an earlier study, pamidronate, a nitrogen-containing bisphosphonate similar to
ZA, failed to show synergetic effect in a combination regime with DTIC in melanoma cells in
vitro [48]. However, the study did not include melanoma cells with known NRAS mutation.
More recently, Niessner et al [70] demonstrated significant synergetic effect of lonafarnib and
sorafenib (a nonselective kinase inhibitor) in melanoma cells with NRAS and BRAF mutations
or double wild-type cells. Our observation is also in line with studies from other tumor types
where ZA has already been found to be additive or synergistic with certain chemotherapeutic
drugs [71–73].
In summary our findings suggest that prenylation inhibition may be able to target melano-
ma cells with mutant NRAS or with mutant BRAF and PTEN. Importantly, benefit of prenyla-
tion inhibition may strongly depend on the driver oncogenic mutations present in a tumor.
Furthermore, based on our preclinical findings, additional prenylation inhibitors need to be de-
veloped or investigated that have improved pharmacological properties in order to be effective
against NRAS mutant malignant melanoma.
Supporting Information
S1 Fig. Immunoblot staining for PTEN expression of all 13 cell lines. Representative blots
for the evaluation of PTEN expression in the examined melanoma cell lines.
(TIF)
S2 Fig. Immunoblot staining for p-Akt for two NRAS mutant cell lines. Representative blots
of the effect of 48hs zoledronic acid (ZA).
(TIF)
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S3 Fig. Cell viability in NRAS mutant melanoma cells (M2met and VM-15) after combina-
tion treatments. Effects of combined treatment with ZA and DTIC (A, B) or cisplatin
(C, D) were investigated using 48hs treatment and SRB assay. Although some additive effect,
no clear synergism could be observed.
(TIF)
S4 Fig. Migration in melanoma cells after combined treatment with zoledronic acid (ZA)
and DTIC. ZA treatment increased the migratory activity of BRAF mutant cells, but interest-
ingly, DTIC had no effect on ZA induced changes in cell migration. In NRAS mutant and dou-
ble wild-type cells neither the single nor the combined treatment changed migration activity.
Data shown as average ± SD are results of three independent measurements. Asterisks indicate
significance of p< 0.05 by Kruskal-Wallis and Dunn’s multiple comparison test.
(TIF)
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